Sangamo Therapeutics, Inc. (0R1D.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
As of 06:58PM BST. Market open.
| Previous close | 0.5412 |
| Open | 0.0000 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | 47,193 |
| Market cap | 629,665 |
| Beta (5Y monthly) | 1.40 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.2130 |
| Earnings date | 09 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksCardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 12% and 86.36%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Business WireSangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
RICHMOND, Calif., May 02, 2024--Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
Business WireSangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
RICHMOND, Calif., April 22, 2024--Sangamo Therapeutics to Present Neurology Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at ASGCT
© 2024 Yahoo. All rights reserved.